Close
Achema middle east
swop processing & packaging

PHARMASEAL’s Engility platform fights off competition to be selected by award-winning US Medical Device company

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

PHARMASEAL, a provider of clinical trial management and governance solutions, announced today that it has secured its first Medical Device customer – an award-winning US-based company providing ultrasound technology.

The Engility® Trial Management Platform was chosen following review of several clinical trial management systems (CTMS). Engility® was selected for its combined CTMS and electronic trial master file (eTMF) capabilities.

Engility’s integrated platform provides users with a higher level of productivity by allowing clinical teams to operate with one single system. Ultimately it saves time on setup, implementation, user training and validation. This allows better and more integrated workflows and a consistent user experience across both capabilities.

Daljit Cheema, Founder and CEO of PHARMASEAL, commented, “This news is a great start to the year for PHARMASEAL and we are delighted Engility® has been selected and licensed to support its first medical device customer to improve the management and control of their device trials.

Furthermore, this will allow us to work with more global medical device companies who have expressed an interest in Engility® allowing for smarter management and execution of medical device clinical trials.”

Engility® by PHARMASEAL is an innovative enterprise trial management system platform offering rapid deployment. Its intuitive user experience and interoperability with other eClinical solutions means it is ideally placed to optimise clinical trial governance and oversight.

Daljit further commented, “We have the vision to create smarter technologies for the improvement of human health and we are excited to see what possibilities emerge from this collaboration for transforming the future of healthcare.”

About PHARMASEAL

PHARMASEAL was founded in 2016 by a team of industry leaders who share a vision to create smarter technologies and innovative products for the improvement of human health. The company’s platform Engility® simplifies the management and control of clinical trials for biopharmaceutical and medical device companies. Engility® utilises advanced engineering offering enterprise management with rapid deployment, an intuitive user interface and interoperability with other eClinical applications to optimise trial governance and oversight.

Latest stories

Related stories

Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. (October 16, 2025) – Thermo Fisher Scientific Inc....

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »